Prasugrel Tablet, Film Coated
Product Images NDC 51407-445

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Prasugrel (NDC 51407-445). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

51407-444-30lb.jpg (51407 444 30lb)

51407-444-30lb.jpg (51407 444 30lb)
FDA Label Image

51407-445-30lb.jpg (51407 445 30lb)

51407-445-30lb.jpg (51407 445 30lb)
This is a medication label for Prasugrel. Each film-coated tablet contains 10 mg Prasugrel hydrochloride. It is advised to keep this and all medication out of reach of children, protect from moisture, keep and dispense only in the original container, and do not remove desiccant from bottles. The pharmacist should dispense the accompanying medication guide to each patient. Do not use the medication if the inner seal is missing or broken.*
FDA Label Image

Figure 1: Non-cabg-related Timi Major Or Minor Bleeding Events. (Image 01)

Figure 1: Non-cabg-related Timi Major Or Minor Bleeding Events. (Image 01)
FDA Label Image

Prasugrel Hydrochloride Structural Formula (Image 02)

Prasugrel Hydrochloride Structural Formula (Image 02)
FDA Label Image

Figure 2: Inhibition (mean ± Sd) Of 20 μm Adp-induced Platelet Aggregation (ipa) Measured By Light Transmission Aggregometry After Prasugrel 60 mg. (Image 03)

Figure 2: Inhibition (mean ± Sd) Of 20 μm Adp-induced Platelet Aggregation (ipa) Measured By Light Transmission Aggregometry After Prasugrel 60 mg. (Image 03)
FDA Label Image

Figure 3: Time To First Event Of Cv Death, Mi, Or Stroke (triton-timi 38). (Image 04)

Figure 3: Time To First Event Of Cv Death, Mi, Or Stroke (triton-timi 38). (Image 04)
This appears to be a chart or graph showing the percentage of cardiovascular death, nonfatal stroke, and nonfatal M (which is unclear what it stands for) over time (measured in days) after using something called Prasugrel Tobets in patients with UANSTEMI. The chart shows a statistically significant result with a p-value of 0.002.*
FDA Label Image

Figure 4: Subgroup Analyses For Time To First Event Of Cv Death, Mi, Or Stroke (hr And 95% Ci; Triton-timi 38) – Ua/nstemi Patients. (Image 05)

Figure 4: Subgroup Analyses For Time To First Event Of Cv Death, Mi, Or Stroke (hr And 95% Ci; Triton-timi 38) – Ua/nstemi Patients. (Image 05)
FDA Label Image

Figure 5: Subgroup Analyses For Time To First Event Of Cv Death, Mi, Or Stroke (hr And 95% Ci; Triton-timi 38) – Stemi Patients. (Image 06)

Figure 5: Subgroup Analyses For Time To First Event Of Cv Death, Mi, Or Stroke (hr And 95% Ci; Triton-timi 38) – Stemi Patients. (Image 06)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.